Kairos Pharma, LTD.’s (NYSEAMERICAN:KAPA) Lock-Up Period To Expire Tomorrow

Kairos Pharma’s (NYSEAMERICAN:KAPAGet Free Report) lock-up period will end on Monday, March 17th. Kairos Pharma had issued 1,550,000 shares in its initial public offering on September 16th. The total size of the offering was $6,200,000 based on an initial share price of $4.00. After the end of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Kairos Pharma in a report on Wednesday, February 26th.

View Our Latest Stock Report on KAPA

Kairos Pharma Price Performance

Shares of Kairos Pharma stock opened at $0.99 on Friday. The firm’s 50-day moving average price is $1.40. Kairos Pharma has a 52-week low of $0.85 and a 52-week high of $4.00.

About Kairos Pharma

(Get Free Report)

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.

Read More

Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.